A3 adenosine receptor agonist prevents the development of paclitaxel-induced neuropathic pain by modulating spinal glial-restricted redox-dependent signaling pathways

A3 adenosine receptor agonist attenuates neuropathic pain by suppressing activation of microglia and convergence of nociceptive inputs in the spinal dorsal horn

Experimental Brain Research ◽

10.1007/s00221-018-5377-1 ◽

2018 ◽

Vol 236 (12) ◽

pp. 3203-3213 ◽

Cited By ~ 11

Author(s):

Ryuji Terayama ◽

Mitsuyasu Tabata ◽

Kotaro Maruhama ◽

Seiji Iida

Keyword(s):

Neuropathic Pain ◽

Dorsal Horn ◽

Adenosine Receptor ◽

Receptor Agonist ◽

Spinal Dorsal Horn ◽

Spinal Dorsal ◽

Efficient, large-scale synthesis and preclinical studies of MRS5698, a highly selective A3 adenosine receptor agonist that protects against chronic neuropathic pain

Purinergic Signalling ◽

10.1007/s11302-015-9459-2 ◽

2015 ◽

Vol 11 (3) ◽

pp. 371-387 ◽

Cited By ~ 24

Author(s):

Dilip K. Tosh ◽

Janak Padia ◽

Daniela Salvemini ◽

Kenneth A. Jacobson

Keyword(s):

Neuropathic Pain ◽

Adenosine Receptor ◽

Receptor Agonist ◽

Large Scale ◽

Preclinical Studies ◽

Chronic Neuropathic Pain ◽

A3 Adenosine Receptor ◽

Large Scale Synthesis

Abstract 5567: Anti-angiogenic activity of Thio-Cl-IB-MECA, a novel A3 adenosine receptor agonist, by regulating of PI3K/AKT/mTOR and ERK signaling pathways in endothelial cells

10.1158/1538-7445.am2015-5567 ◽

2015 ◽

Author(s):

Jedo Oh ◽

Gi Dae Kim ◽

Lak Shin Jeong ◽

Sang Kook Lee

Keyword(s):

Endothelial Cells ◽

Signaling Pathways ◽

Adenosine Receptor ◽

Receptor Agonist ◽

Erk Signaling ◽

Angiogenic Activity ◽

CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver

Journal of Cellular Physiology ◽

10.1002/jcp.22593 ◽

2011 ◽

Vol 226 (9) ◽

pp. 2438-2447 ◽

Cited By ~ 48

Author(s):

S. Cohen ◽

S.M. Stemmer ◽

G. Zozulya ◽

A. Ochaion ◽

R. Patoka ◽

...

Keyword(s):

Adenosine Receptor ◽

Receptor Agonist ◽

A3 Adenosine Receptor ◽

Anti Inflammatory

Suppression of inflammation response by a novel A3 adenosine receptor agonist thio-Cl-IB-MECA through inhibition of Akt and NF-κB signaling

Immunobiology ◽

10.1016/j.imbio.2011.03.008 ◽

2011 ◽

Vol 216 (9) ◽

pp. 997-1003 ◽

Cited By ~ 27

Author(s):

Hak-Sun Lee ◽

Hwa-Jin Chung ◽

Hyuk Woo Lee ◽

Lak Shin Jeong ◽

Sang Kook Lee

Keyword(s):

Adenosine Receptor ◽

Receptor Agonist ◽

Inflammation Response ◽

A3 Adenosine Receptor Agonist Inhibited Survival of Breast Cancer Stem Cells via GLI-1 and ERK1/2 Pathway

Journal of Cellular Biochemistry ◽

10.1002/jcb.25945 ◽

2017 ◽

Vol 118 (9) ◽

pp. 2909-2920 ◽

Cited By ~ 12

Author(s):

Seyyed Mehdi Jafari ◽

Mojtaba Panjehpour ◽

Mahmoud Aghaei ◽

Hamid Reza Joshaghani ◽

Seyed Ehsan Enderami

Keyword(s):

Breast Cancer ◽

Stem Cells ◽

Cancer Stem Cells ◽

Adenosine Receptor ◽

Receptor Agonist ◽

Breast Cancer Stem Cells ◽

A3 Adenosine Receptor ◽

Gli 1

CF 101,* an A3 adenosine receptor agonist shows promise for rheumatoid arthritis,

Inpharma Weekly ◽

10.2165/00128413-200715970-00010 ◽

2007 ◽

Vol &NA; (1597) ◽

pp. 6

Author(s):

&NA;

Keyword(s):

Rheumatoid Arthritis ◽

Adenosine Receptor ◽

Receptor Agonist ◽

A3 adenosine receptor agonist potentiates natural killer cell activity

International Journal of Oncology ◽

10.3892/ijo.23.4.1245 ◽

2003 ◽

Cited By ~ 10

Author(s):

Arie Harish ◽

Gil Hohana ◽

Pnina Fishman ◽

Oshra Arnon ◽

Sara Bar-Yehuda

Keyword(s):

Natural Killer Cell ◽

Natural Killer ◽

Adenosine Receptor ◽

Receptor Agonist ◽

Natural Killer Cell Activity ◽

Killer Cell ◽

Cell Activity ◽

Killer Cell Activity ◽

Post-ischaemic administration of a3 adenosine receptor agonist ameliorates myocardial ischaemia–reperfusion injury via ERK 1/2

Journal of Molecular and Cellular Cardiology ◽

10.1016/j.yjmcc.2006.03.160 ◽

2006 ◽

Vol 40 (6) ◽

pp. 974 ◽

Cited By ~ 1

Author(s):

A. Hussain ◽

H. Al-Rajaibi ◽

P. Karjian ◽

H.L. Maddock

Keyword(s):

Reperfusion Injury ◽

Myocardial Ischaemia ◽

Adenosine Receptor ◽

Receptor Agonist ◽

Ischaemia Reperfusion Injury ◽

Ischaemia Reperfusion ◽

A phase II, multi-center study of a new non-cytotoxic A3 adenosine receptor agonist CF101, dose-finding (randomized blinded) in patients (pts)with refractory metastatic colorectal cancer

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.3153 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3153-3153 ◽

Cited By ~ 2

Author(s):

S. M. Stemmer ◽

A. Shani ◽

B. Klein ◽

M. H. Silverman ◽

I. Lorber ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Adenosine Receptor ◽

Receptor Agonist ◽

Dose Finding ◽

A3 Adenosine Receptor ◽

Multi Center Study ◽

Center Study